Akebia Therapeutics (AKBA) EBT Margin (2017 - 2026)

Akebia Therapeutics (AKBA) has 10 years of EBT Margin data on file, last reported at 16.67% in Q1 2026.

• On a quarterly basis, EBT Margin fell 2733.0% year-over-year to 16.67% in Q1 2026; TTM through Mar 2026 was 8.07%, a 1643.0% increase from a year earlier, with the FY2025 full-year figure at 1.58%, up 4176.0% from the prior year.
• EBT Margin for Q1 2026 stood at 16.67%, up from 19.5% in the prior quarter.
• Over the last five years, EBT Margin for AKBA reached as high as 24.83% in Q2 2022 and fell as low as 81948.68% in Q1 2022.
• Historically, EBT Margin has averaged 4844.7% across 5 years, with a median of 19.66% in 2024.
• Across the five-year window, EBT Margin tumbled 8181937 bps in 2022 and jumped 8188150 bps in 2023, its largest moves.
• Year by year, EBT Margin stood at 7.39% in 2022, then soared by 115 bps to 1.09% in 2023, then plunged by 4589 bps to 49.04% in 2024, then surged by 60 bps to 19.5% in 2025, then increased by 14 bps to 16.67% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 16.67% in Q1 2026, 19.5% in Q4 2025, and 1.97% in Q3 2025.